The pharmaceutical value chain model depicted in Figure 1 covers a full range of activities that are required to bring a product from conception to final consumer. The key players in the chain are ...

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the ways that tariffs disrupt pharma supply ...

How can I maximise value by using third parties ... Johnathon Marshall is a director of PricewaterhouseCoopers’ Pharmaceutical Supply Chain practice. He can be contacted at + 44 (0)207 804 ...

With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the ...

Following are six reasons why pharmaceutical and life sciences companies must prioritize track-and-trace technology in their ...

To further enhance the value of the RNN model ... By addressing the scarcity of prior studies on sequential delay issues in pharmaceutical supply chains, this project also contributes valuable ...

Ron Lanton, Partner, Lanton Law, examines the legal and economic impacts of reciprocal tariffs on the pharma supply chain, including potential disruptions and increased drug costs.

"The measures noted above not only improve manufacturing operations, but also play a role in making the entire pharmaceutical value chain more sustainable, with CPOs leading the way," von Kienlin ...

Zydus Lifesciences is working to advance its position in the global pharmaceutical sector by increasing its focus on medical ...

and reduce costs across the pharmaceutical value chain. Pharma 4.0 applies to various stages of the pharmaceutical process, including: Consumers are increasingly looking for transparency in drug ...